Characteristics of the First Cohort of Standard-Risk Patients Undergoing Allogeneic Nonmyeloablative Stem Cell Transplantation With Matched Related Donors
| UPN . | Age . | Diagnosis . | D → H . |
|---|---|---|---|
| 1031 | 50 | CML/CP | M → M |
| 1052 | 51 | 2°AML 1st CR | M → F |
| 1053 | 56 | CML/CP | M → M |
| 1057 | 16 | β-Thalassemia major | M → F |
| 1073 | 19 | AML 2nd CR | F → F |
| 1077 | 19 | AML 1st CR | M → F |
| 1080 | 12 | ALL 2nd CR | F → M |
| 1088 | 37 | NHL, chemotherapy resist. | M → M |
| 1093 | 26 | AML 1st CR | M → F |
| 1098 | 61 | NHL, chemotherapy resist. | F → M |
| 1099 | 41 | MDS | M → M |
| 1109* | 1 | AML 1st CR | M → F |
| 1111-151 | 51 | Multiple myeloma | F → M |
| 1114 | 10 | Fanconi's anemia | M → F |
| 1119 | 2 | JCML | M → M |
| 1123 | 31 | Blackfan Diamond anemia | F → F |
| 1124 | 20 | AML 1st CR | M → F |
| 1131 | 34 | CML/AP | F → M |
| 1133 | 29 | AML 1st CR | F → M |
| 1135 | 33 | CML/CP | F → F |
| 1137 | 38 | CML/CP | M → M |
| 1140 | 3 | Gaucher's disease | M → F |
| 1141 | 39 | AML 1st CR | M → M |
| 1143 | 36 | CML/CP | F → M |
| 1156 | 46 | ALL 1st CR | M → M |
| 1158 | 46 | CML/CP | M → M |
| UPN . | Age . | Diagnosis . | D → H . |
|---|---|---|---|
| 1031 | 50 | CML/CP | M → M |
| 1052 | 51 | 2°AML 1st CR | M → F |
| 1053 | 56 | CML/CP | M → M |
| 1057 | 16 | β-Thalassemia major | M → F |
| 1073 | 19 | AML 2nd CR | F → F |
| 1077 | 19 | AML 1st CR | M → F |
| 1080 | 12 | ALL 2nd CR | F → M |
| 1088 | 37 | NHL, chemotherapy resist. | M → M |
| 1093 | 26 | AML 1st CR | M → F |
| 1098 | 61 | NHL, chemotherapy resist. | F → M |
| 1099 | 41 | MDS | M → M |
| 1109* | 1 | AML 1st CR | M → F |
| 1111-151 | 51 | Multiple myeloma | F → M |
| 1114 | 10 | Fanconi's anemia | M → F |
| 1119 | 2 | JCML | M → M |
| 1123 | 31 | Blackfan Diamond anemia | F → F |
| 1124 | 20 | AML 1st CR | M → F |
| 1131 | 34 | CML/AP | F → M |
| 1133 | 29 | AML 1st CR | F → M |
| 1135 | 33 | CML/CP | F → F |
| 1137 | 38 | CML/CP | M → M |
| 1140 | 3 | Gaucher's disease | M → F |
| 1141 | 39 | AML 1st CR | M → M |
| 1143 | 36 | CML/CP | F → M |
| 1156 | 46 | ALL 1st CR | M → M |
| 1158 | 46 | CML/CP | M → M |
*Donor (brother) was incompatible at one A and one C loci, with positive MLR in the direction of host-versus-graft.
Patient conditioned with cytoxan instead of busulfan.